Price
CHART BY
Frequently asked questions
What is ACADIA Pharm's market capitalization?
The market capitalization of ACADIA Pharm is $4.52B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is ACADIA Pharm's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for ACADIA Pharm is 17.19. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for ACADIA Pharm?
ACADIA Pharm's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $1.554. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for ACADIA Pharm's stock?
Currently, 20 analysts cover ACADIA Pharm's stock, with a consensus target price of $29.79. Analyst ratings provide insights into the stock's expected performance.
What is ACADIA Pharm's revenue over the trailing twelve months?
Over the trailing twelve months, ACADIA Pharm reported a revenue of $1.05B.
What is the EBITDA for ACADIA Pharm?
ACADIA Pharm's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $108.46M. EBITDA measures the company's overall financial performance.
What is the free cash flow of ACADIA Pharm?
ACADIA Pharm has a free cash flow of $197.81M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does ACADIA Pharm have, and what sector and industry does it belong to?
ACADIA Pharm employs approximately 654 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of ACADIA Pharm's shares?
The free float of ACADIA Pharm is 167.35M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $4.52B
- EPS (TTM)
- $1.554
- Free Float
- 167.35M
- P/E ratio (TTM)
- 17.19
- Revenue (TTM)
- $1.05B
- EBITDA (TTM)
- $108.46M
- Free Cashflow (TTM)
- $197.81M
Pricing
- 1D span
- $26.12$27.14
- 52W span
- $13.40$28.34
Analyst Ratings
The price target is $29.79 and the stock is covered by 20 analysts.
Buy
13
Hold
6
Sell
1
Information
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
- Employees
- 654
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- ACAD
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet